Selecta inks discovery deal with Sanofi worth up to $900M


Vaccine outfit Selecta Biosciences has signed an agreement with Sanofi ($SNY) to discover antigen-specific immunotherapies for food allergies, and the deal includes rights to an initial therapy with the option to develop two more. Selecta is due up to $900 million in milestones, plus a cut of sales. Report